Kura Oncology (NASDAQ:KURA) Earns Buy Rating from HC Wainwright

Kura Oncology (NASDAQ:KURA - Get Free Report)'s stock had its "buy" rating restated by equities researchers at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $40.00 target price on the stock.

A number of other equities research analysts also recently weighed in on KURA. UBS Group dropped their price objective on Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Scotiabank reduced their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research note on Wednesday, January 8th. Cantor Fitzgerald raised shares of Kura Oncology to a "strong-buy" rating in a report on Tuesday, March 4th. JMP Securities reissued a "market outperform" rating and issued a $28.00 price objective on shares of Kura Oncology in a research report on Thursday, February 6th. Finally, Wedbush restated an "outperform" rating and set a $36.00 target price on shares of Kura Oncology in a research note on Tuesday, April 8th. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Kura Oncology has an average rating of "Moderate Buy" and an average price target of $25.50.

Kura Oncology Trading Down 0.4 %

Kura Oncology stock traded down $0.03 during trading hours on Monday, hitting $6.41. The company had a trading volume of 299,289 shares, compared to its average volume of 1,146,161. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The firm has a market cap of $517.38 million, a P/E ratio of -2.71 and a beta of 0.83. The company has a 50-day moving average price of $6.88 and a two-hundred day moving average price of $9.93. Kura Oncology has a 1 year low of $5.41 and a 1 year high of $23.48.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. On average, sell-side analysts anticipate that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Activity at Kura Oncology

In related news, SVP Thomas James Doyle sold 4,949 shares of the firm's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares of the company's stock, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares of the company's stock, valued at $694,551.11. The trade was a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock worth $92,307 over the last three months. Company insiders own 6.40% of the company's stock.

Institutional Trading of Kura Oncology

A number of institutional investors have recently made changes to their positions in KURA. China Universal Asset Management Co. Ltd. increased its stake in shares of Kura Oncology by 11.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company's stock worth $144,000 after acquiring an additional 1,750 shares during the last quarter. Rhumbline Advisers raised its position in Kura Oncology by 2.0% in the fourth quarter. Rhumbline Advisers now owns 99,991 shares of the company's stock valued at $871,000 after purchasing an additional 1,923 shares during the period. Harbor Capital Advisors Inc. lifted its stake in shares of Kura Oncology by 4.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock valued at $430,000 after purchasing an additional 2,076 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Kura Oncology by 19.9% during the 4th quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company's stock worth $120,000 after purchasing an additional 2,285 shares during the period. Finally, MetLife Investment Management LLC raised its holdings in Kura Oncology by 6.6% in the 4th quarter. MetLife Investment Management LLC now owns 44,828 shares of the company's stock valued at $390,000 after buying an additional 2,776 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.